Evidence map›Paper›PMID 39676462›Full record

ArticleThoracic cancer2025

Tepotinib for the Treatment of Lung Adenocarcinoma Harboring MET Y1003N Point Mutation: A Case Report.

Yukihiro Umeda, Satomi Kimura, Junya Kimura, Yoshiaki Imamura, Tamotsu Ishizuka

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yukihiro UmedaDepartment of Respiratory Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, Fukui, Japan.ORCID https://orcid.org/0000-0002-9826-6856
Satomi KimuraDepartment of Respiratory Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, Fukui, Japan.
Junya KimuraDivision of Diagnostic Pathology/Surgical Pathology, University of Fukui Hospital, Eiheiji, Fukui, Japan.
Yoshiaki ImamuraDivision of Diagnostic Pathology/Surgical Pathology, University of Fukui Hospital, Eiheiji, Fukui, Japan.
Tamotsu IshizukaDepartment of Respiratory Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, Fukui, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mesenchymal-epithelial transition factor (MET) Y1003 mutation, like MET ex14 skipping, is an oncogenic driver mutation that suppresses MET degradation. Herein, we report the case of a 63-year-old female patient with lung adenocarcinoma harboring the MET Y1003N mutation, who was treated with tepotinib, a selective type 1b MET tyrosine kinase inhibitor. To the best of our knowledge, no such cases have been reported. The woman was referred to our hospital with the chief complaint of chest pain. After a detailed examination, she was diagnosed with stage IVB lung adenocarcinoma. Next-generation sequencing revealed an MET Y1003N mutation in the tumor. Tepotinib was administered as the eighth-line treatment, and the best overall response was a partial response that lasted for 8 months. In lung adenocarcinomas harboring the MET Y1003 mutation, selective type 1b MET tyrosine kinase inhibitors may be an important treatment option, even in heavily pretreated settings.

Indexed as

Adenocarcinoma of LungLung NeoplasmsPoint MutationProtein Kinase InhibitorsProto-Oncogene Proteins c-metPyridazinesPyrimidinesFemaleHumansMiddle AgedPiperidinesMET protein, humanPiperidinesProtein Kinase InhibitorsProto-Oncogene Proteins c-metPyridazinesPyrimidinestepotinibadenocarcinoma of lungsMET Y1003mutationtepotinibtyrosine kinase inhibitors

Identifiers

PMID39676462
PMCPMC11739454

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.